SCHEMBL3362602

SCHEMBL3362602

CC1=NNC(=O)/C1=C/c1ccc(-c2cccc(C(=O)O)c2)o1

nearest known ligand 0.66

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PIM1 P11309 1/20 0.66
POLB P06746 7/20 0.60
MEN1 O00255 5/20 0.60
KMT2A Q03164 5/20 0.60
GFER P55789 1/20 0.60
CTDSP1 Q9GZU7 1/20 0.60
GSK3A P49840 3/20 0.59
PIK3CG P48736 2/20 0.59
GSK3B P49841 2/20 0.59
BRAF P15056 2/20 0.58
TDP1 Q9NUW8 5/20 0.57
KDM4E B2RXH2 4/20 0.57
L3MBTL1 Q9Y468 3/20 0.57
ALDH1A1 P00352 2/20 0.57
MAPT P10636 4/20 0.56
RECQL P46063 4/20 0.56
PSMD14 O00487 3/20 0.56
MMP2 P08253 3/20 0.56
MCL1 Q07820 3/20 0.56
KEAP1 Q14145 1/20 0.56

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3362606 1.00 PIM1 (0.66) PIM1POLBMEN1KMT2AGFER
SCHEMBL19653407 0.81 KMT2A (0.71) POLBMEN1KMT2ACTDSP1TDP1
SCHEMBL3367002 0.80 PIM1 (0.67) PIM1POLBMEN1KMT2AGFER
SCHEMBL12989976 0.80 PIM1 (0.67) PIM1POLBMEN1KMT2AGFER
SCHEMBL3366998 0.80 PIM1 (0.67) PIM1POLBMEN1KMT2AGFER
SCHEMBL13587005 0.80 GSK3A (0.81) PIM1POLBMEN1KMT2AGFER
SCHEMBL700411 0.79 PIM1 (1.00) PIM1POLBMEN1KMT2AGFER
SCHEMBL31434334 0.79 PIM1 (1.00) PIM1POLBMEN1KMT2AGFER
SCHEMBL700410 0.79 PIM1 (1.00) PIM1POLBMEN1KMT2AGFER
SCHEMBL31434402 0.79 PIM1 (0.73) PIM1POLBMEN1KMT2AGFER

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20100331315-A1 RHODANINES AND RELATED HETEROCYCLES AS KINASE INHIBITORS SENHWA BIOSCIENCES, INC. (TW) 2010-12-30 US disclosed
US-20100331315-A1 RHODANINES AND RELATED HETEROCYCLES AS KINASE INHIBITORS SENHWA BIOSCIENCES, INC. (TW) 2010-12-30 US disclosed
US-20100331315-A1 RHODANINES AND RELATED HETEROCYCLES AS KINASE INHIBITORS SENHWA BIOSCIENCES, INC. (TW) 2010-12-30 US disclosed
WO-2010148351-A1 RHODANINES AND RELATED HETEROCYCLES AS KINASE INHIBITORS CYLENE PHARMACEUTICALS, INC. (US) 2010-12-23 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100331315-A1 RHODANINES AND RELATED HETEROCYCLES AS KINASE INHIBITORS PIM2, PIM1, CDK2 PIM1 2/4885POLB 2065/4885MEN1 2930/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.